GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (AQSE:MYIG) » Definitions » EPS (Basic)

Mydecine Innovations Group (AQSE:MYIG) EPS (Basic) : £-1.17 (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mydecine Innovations Group EPS (Basic)?

Mydecine Innovations Group's basic earnings per share (Basic EPS) for the three months ended in Jun. 2024 was £-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was £-1.17.

Mydecine Innovations Group's EPS (Diluted) for the three months ended in Jun. 2024 was £-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-1.17.

Mydecine Innovations Group's EPS without NRI for the three months ended in Jun. 2024 was £-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -1.05.

During the past 3 years, the average EPS without NRI Growth Rate was 55.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 56.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Mydecine Innovations Group's highest 3-Year average EPS without NRI Growth Rate was 73.40% per year. The lowest was -77.70% per year. And the median was 51.50% per year.


Mydecine Innovations Group EPS (Basic) Historical Data

The historical data trend for Mydecine Innovations Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group EPS (Basic) Chart

Mydecine Innovations Group Annual Data
Trend Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.81 -7.00 -3.63 -0.65 -0.40

Mydecine Innovations Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.94 -0.20 -0.01 -0.02

Mydecine Innovations Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mydecine Innovations Group's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-12.335-0)/30.697
=-0.40

Mydecine Innovations Group's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.531-0)/61.191
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group  (AQSE:MYIG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mydecine Innovations Group EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group Business Description

Traded in Other Exchanges
Address
1890 – 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group Headlines

No Headlines